[{"id":"e7a174b3-87f7-443a-b744-e941f8c6673e","acronym":"KEYNOTE-E20","url":"https://clinicaltrials.gov/study/NCT05311618","created_at":"2022-04-05T13:52:37.035Z","updated_at":"2025-02-25T16:17:32.726Z","phase":"Phase 1","brief_title":"Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05311618 - KEYNOTE-E20","lead_sponsor":"NGM Biopharmaceuticals, Inc","biomarkers":" CD8 • CD163 • MMP9","pipe":"","alterations":" ","tags":["CD8 • CD163 • MMP9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NGM438"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 05/11/2022","start_date":" 05/11/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-01"}]